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DObjective: To define the objective and subjective measures of aortic stenosis (AS) severity linked to survival
after diagnosis in community practice.
Methods: All 360 Olmsted County, Minnesota residents (74  14 years; 44% men) with AS diagnosed from
1988 to 1997 by echocardiography and without life-threatening comorbid conditions were enrolled. The presen-
tation at first diagnosis, outcomes (mortality, heart failure, cardiac surgery), and coherence of guideline-based
criteria for severe AS were analyzed.
Results: The presentation was challenging. Cardiac symptoms were frequent (59%) and unassociated with the
AS severity (all P>.13). Of the patients with severe AS, as determined by a valve area less than 1.0 cm2, 67%
had low gradient AS (40 mm Hg). An aortic valve area less than 1.0 cm2 was the only objective measure in-
dependently determining survival (adjusted risk ratio, 1.81; 95% confidence interval [CI], 1.19–2.70; P<.01)
and heart failure (adjusted risk ratio, 2.3; 95% CI, 1.3–4.0; P<.01), even in patients with low-gradient AS and/
or an ejection fraction of 50% or greater. Excess mortality (vs expected mortality) occurred with an aortic valve
area of less than 1.0 cm2 (risk ratio, 1.78; 95% CI, 1.33–2.35; P<.001) even without symptoms (risk ratio, 1.65;
95% CI, 1.05–2.47; P ¼ .02). Aortic valve replacement, ultimately performed in only 45% of those with an
aortic valve area less than 1.0 cm2, reduced mortality (risk ratio, 0.61; 95% CI, 0.39–0.94; P ¼ .02) and heart
failure (risk ratio, 0.29; 95% CI, 0.13–0.64; P<.01).
Conclusions: In community practice, AS affects elderly patients, and its presentation is challenging owing to the
high frequency of low-gradient severe AS despite a normal ejection fraction and because symptoms are fre-
quently not specific to AS. Consequently, aortic valve replacement is seldom performed despite its considerable
benefit. Physicians should be aware that an aortic valve area of less than 1.0 cm2 predicts for unfavorable out-
comes, irrespective of symptoms or gradient. Thus, such patients should undergo a thorough evaluation to detect
those who could benefit from aortic valve replacement, despite their challenging presentation. (J Thorac Cardi-
ovasc Surg 2012;144:1421-7)Aortic stenosis (AS) in the current era is predominantly a de-
generative disease of the elderly.1,2 Aortic valve replacement
(AVR) is the only established treatment of AS3; however, re-
cent clinical series4,5 have shown that AVR is inconsistently
offered to these older patients. Although symptoms remain
the main indication for AVR in patients with AS,3 the inter-
pretation of symptoms, in particular, shortness of breath in
the elderly, can be challenging, either because of lack of
symptoms owing to inactivity or because of age-related
confounders such as coronary artery disease or chronic lung
disease that affect symptom reliability.4,6,7 Moreover, an
often-held tenet is that in patients with severeAS, the absencee Divisions of Cardiovascular Diseasesa and Cardiovascular Surgeryb and
on of Biostatistics,c Mayo Clinic, Rochester, Minn.
dy was funded by the Mayo Foundation.
ures: Authors have nothing to disclose with regard to commercial support.
d for publication June 29, 2011; revisions received Aug 26, 2011; accepted
blication Sept 26, 2011; available ahead of print Feb 16, 2012.
for reprints: Maurice Enriquez-Sarano, MD, Mayo Clinic, 200 First Street
west, Rochester, MN 55905 (E-mail: sarano.maurice@mayo.edu).
23/$36.00
ht 2012 Published by Elsevier Inc. on behalf of The American Association
racic Surgery
016/j.jtcvs.2011.09.075
The Journal of Thoracic and Carof symptoms implies a low risk.8 However, this remains un-
proved. Indeed, recent natural history studies of asymptom-
atic severe AS reported 5-year survival of 83%,9 60%,6 or
38%,10 which compared with the expected survival ranged
fromnormal life expectancy to notable or even excessmortal-
ity. Uncertainty regarding AS hemodynamic severity is an-
other major reason for not performing AVR because of
increased operative mortality and morbidity in the elderly.5
AccurategradingofASseverity is therefore crucial for the de-
cision to recommend AVR.7 However, objective assessment
of AS severity has also been uncertain. Previous studies
used various surrogates of AS severity that were not always
concordant,6,9,10 and no formal comparison has been made
of the outcome predictive strength of the various AS
indexes and thresholds used, particularly those proposed by
the guidelines. The traditional aortic valve area (AVA),
supposedly directly measuring lesion severity and
a standard for clinical management, in particular, lacks
validation as an AS outcome determinant. Thus, several
unconventional indexes have been proposed as superior
measures of AS severity but lack intrinsic and comparative
outcome analysis.11,12diovascular Surgery c Volume 144, Number 6 1421
Abbreviations and Acronyms
AS ¼ aortic stenosis
AVA ¼ aortic valve area
AVR ¼ aortic valve replacement
CHF ¼ congestive heart failure
EF ¼ ejection fraction
MnG ¼ mean gradient
RR ¼ risk ratio
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DTo complete these knowledge gaps and to reduce selec-
tion bias, we conducted a community (residents of Olmsted
County, Minn) cohort study, enrolling all patients diagnosed
with AS in a geographically defined area. Our aim was to
define the objective and subjective measures of AS severity
that linked to survival after diagnosis.
METHODS
Study Patients
In Olmsted County, Minnesota, Mayo Clinic personnel perform all car-
diology services, including echocardiography, allowing comprehensive
identification of valvular diseases, reliably, compared with systematic pop-
ulation studies.2 Although the Mayo Clinic is a referral center, Olmsted
County residents represent our community practice. The echocardio-
graphic results are prospectively entered into a database from which all
Olmsted County, Minnesota, residents (in- or outpatient) with a first diag-
nosis of native AS (mild or greater, valve area<2.0 cm2 andMnG10 mm
Hg) from January 1, 1988 to December 31, 1997, and at most mild aortic
regurgitation, were retrospectively identified. Of the 491 residents meeting
these criteria, 131 were excluded (age,<18 years; n ¼ 19, life-threatening
comorbid conditions at diagnosis, n ¼ 87; denied research authorization,
n ¼ 23). The remaining 360 patients represent all AS cases diagnosed in
the entire community and formed the study group. The Mayo Institutional
Review Board approved the present study.
Clinical Data
The baseline clinical variables were abstracted from the medical records
as noted by the personal physicians. Symptoms were classified as any car-
diac symptoms (any dyspnea, chest discomfort, syncope or near syncope,
or fatigue), typical AS-associated symptoms (syncope or near syncope,
dyspnea, and probable or classic angina), severe AS-associated symptoms
(syncope, classic angina, and class III-IV dyspnea), and class III-IV symp-
toms for dyspnea or classic angina class III-IV. Follow-up information was
obtained from the medical records, mailed questionnaires, or death certif-
icates and from scripted telephone interviews with the patients or
physicians.
Echocardiographic Doppler Measurements
Index echocardiographic data were captured electronically without al-
teration from our prospective echocardiographic database. AS severity
was assessed using Doppler-derived conventional (AVA, mean gradient
[MnG], and peak velocity) and nonconventional (aortic valve resistance
and strokework loss) measures. AVA, calculated using the continuity equa-
tion,13 was also indexed to the body surface area. From the guidelines,3
mild, moderate, and severe stenosis was defined as AVA 1.5 to 2.0 cm2,
1.0 to 1.5 cm2, and less than 1.0 cm2, respectively. A peak velocity greater
than 4 m/s and MnG greater than 40 mm Hg are guideline-based3 thresh-
olds for severe AS. Valve resistance and left ventricular stroke work loss
were derived.121422 The Journal of Thoracic and Cardiovascular SurStatistical Analysis
Continuous variables are reported as the mean  standard deviation.
Group comparisons used analysis of variance or the Kruskal-Wallis test.
Categorical variables were reported as percentages compared using the
chi-square test. The primary endpoint was survival after diagnosis under
medical management (censored at AVR). A secondary endpoint was con-
gestive heart failure (CHF) development. Event rates were estimated using
the Kaplan-Meier method and compared using the log-rank test. The ex-
pected survival in the age- and sex-matched Minnesota white population
(US census bureau) was compared with the observed survival using
a 1-sample log-rank test. A predictive power comparison for the outcome
determinants used the c-statistic (measure of concordance between the ob-
served and predicted survival from Cox proportional hazards models) sim-
ilar to the area under the curve for binary endpoints.14 Standard errors from
1000 bootstrap samples constructed the 95% confidence intervals (CIs) to
test for differences between predictors. Multivariate models used Cox pro-
portional hazards. AVR during follow-up was tested as a time-dependent
covariate in the Cox proportional hazards models.RESULTS
Baseline Characteristics
The baseline characteristics are summarized in Table 1.
The AVA was less than 1.0 cm2 in 96 (27%), 1.0 to 1.49
cm2 in 175 (49%), and 1.5 cm2 or greater in 89 patients
(25%). A MnG greater than 40 mm Hg and peak velocity
greater than 4m/s was present in 9% and 10%, respectively.
No difference (apart from age) was found in the clinical
characteristics among the AVA groups, particularly regard-
ing the symptoms (Table 1). Although all echocardiographic
measures of AS severity grossly followed theAVA (Table 1),
agreement between themarkers of severeASwas imperfect.
Most patients with a MnG greater than 40 mmHg (94%) or
peak velocity greater than 4 m/s (95%) also had an AVA of
less than 1.0 cm2. However, most patients with an AVA of
less than 1.0 cm2 had a MnG of 40 mm Hg or less (67%)
or even, frequently, a MnG of less than 30 mm Hg (32%)
and peak velocity of 4 m/s or less (64%). Thus, an AVA
less than 1.0 cm2 was the only marker of severe AS in 60
(63%) of 96 ‘‘discordant’’ patients. Patients with discordant
versus concordant stenosis markers had a lower stroke vol-
ume index (34  8 vs 41  9 mL/m2, P<.01) and ejection
fraction (EF, 54%  16% vs 60%  13%, P ¼ .048), al-
though most (67%) had an EF greater than 50%.Outcomes
The follow-up period, available for all (99.7%) but 1 pa-
tient, was 7.5  4.2 years, with 220 deaths noted (10-year
survival, 42%  3%), including 170 receiving medical
treatment (10-year survival, 37%  4%). In 131 patients,
AVR was ultimately performed (10-year survival, 53 
4%), and 301 patients either died or underwent valve re-
placement (10-year survival, 82%  2%).Survival During Medical Management
Clinically, of the symptom categories (any cardiac, typi-
cal, severe, and class III-IV), only class III-IV symptomsgery c December 2012
TABLE 1. Baseline clinical and echocardiographic Doppler characteristics
Variable Overall population (n ¼ 360)
AVA (cm2)
P value<1.0 (n ¼ 96) 1–1.5 (n ¼ 175) 1.5 (n ¼ 89)
Baseline clinical characteristics
Age (yr) 74  14 77  15 74  12 69  15 <.001
Men (n) 158 (44) 43 (45) 73 (42) 42 (47) .68
Symptoms (n)
Any cardiac* 211 (59) 62 (65) 104 (60) 45 (51) .20
Typicaly 165 (46) 54 (56) 76 (43) 35 (39) .25
Severez 74 (21) 21 (21) 37 (21) 17 (19) .15
Class III/IVx 41 (11) 16 (17) 15 (9) 10 (11) .13
Atrial fibrillation (n) 65 (18) 19 (20) 31 (18) 15 (17) .86
Hypertension (n) 208 (58) 52 (54) 100 (57) 56 (63) .47
Coronary disease (n) 101 (28) 25 (26) 47(27) 29 (33) .54
Comorbidity index 4.4  3.1 4.4  3.1 4.4  3.2 4.7  2.8 .54
Systolic blood pressure (mm Hg) 146  22 147  23 145  22 149  21 .57
Creatinine (mg/dL) .62
Mean 1.1 1.0 1.1 1.1
Interquartile range 0.9–1.3 0.9–1.4 0.9–1.2 0.9–1.3
Echocardiographic Doppler measurements
Valve area (cm2) 1.23  0.36 0.79  0.14 1.23  0.14 1.71  0.13 —
Indexed valve area (cm2/m2) 0.68  0.22 0.45  0.10 0.68  0.11 0.94  0.19 <.001
Mean gradient (mm Hg) 22  14 36  19 17  7 14  4 <.001
Peak velocity (m/s) 2.9  0.82 3.8  0.93 2.7  0.48 2.4  0.37 <.001
Aortic velocity ratio 0.37  0.11 0.25  0.06 0.38  0.07 0.48  0.09 <.001
Valve resistance (dynes/s/cm5) 121  89 225  115 95  25 61  10 <.001
Stroke work loss (%) 13  7 19  8 11  4 9  3 <.001
Ejection fraction (%) 60  13 56  15 61  11 60  12 .12
Data presented as mean  standard deviation or numbers, with percentages in parentheses. AVA, Aortic valve area. *Any cardiac symptoms: typical or atypical chest pain or
discomfort, dyspnea of any degree, syncope or near syncope, or fatigue. yTypical symptoms: syncope or near syncope, dyspnea of any degree and probable or typical angina.
zSevere symptoms: syncope, typical angina, or class III-IV dyspnea. xClass III or IV dyspnea (New York Heart Association classification) or typical angina (Canadian classi-
fication).
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Dpredicted survival during medical management (risk ratio
[RR], 2.77; 95% CI, 1.48–5.19; P ¼ .001 on univariate
analysis; and RR, 1.81; 95% CI, 1.19–2.77; P ¼ .009,
adjusting for age, sex, Charlson comorbidity index, history
of atrial fibrillation, hypertension, coronary disease, and
stroke/transient ischemic attack). Forcing into the models,
lower symptom categories or individual symptoms yielded
no additional marker of survival or model strength (all
P>.10). However, class III-IV symptoms were insensitive
in predicting mortality because they were present in only 29
(17%) of those who died during follow-up.
Of the Doppler echocardiographic measures of AS sever-
ity, on univariate analysis, AVA less than 1.0 cm2 (RR, 3.27;
95% CI, 2.33–4.61; P<.001), MnG greater than 40 mm Hg
(RR, 2.47; 95% CI, 1.32–4.61; P¼ .012), and peak velocity
greater than 4 m/s (RR, 2.21; 95% CI, 1.18–3.79; P¼ .016)
predicted survival during medical management. Compari-
sons using c-statistics showed that for predicting survival,
an AVA less than 1.0 cm2 is superior to MnG greater than
40 mm Hg (P<.001) or peak velocity greater than 4 m/s
(P< .001). An indexed (<0.6 cm2/m2) versus unindexed
(<1.0 cm2) AVA did not add predictive power (P¼ .13). The
aortic velocity ratio, stroke work loss, and valve resistanceThe Journal of Thoracic and Carwere less powerful predictors of survival than the AVA (all
P< .01). On multivariate analysis, an AVA less than 1.0
cm2 was the only measure of AS severity independently pre-
dictive of survival during medical management. Adjusting
for age, sex, comorbidity score, history of hypertension, atrial
fibrillation, coronary disease, and stroke/transient ischemic
attack, an AVA less than 1.0 cm2 independently predicted
survival (adjusted RR, 1.81; 95% CI, 1.19–2.70; P<.01),
along with EF (adjusted RR, 0.98; 95% CI, 0.967–0.99;
per 1-point increase; P< .01) and class III-IV symptoms
(adjusted RR, 1.69; 95% CI, 1.08–2.56; P ¼ .023).
An AVA less than 1.0 cm2 was associated with lower
5- and 8-year survival during medical management (40%
6% and 18%  6%, respectively) compared with an
AVA of 1.0 to 1.5 cm2 (73% 3% and 54% 4%, respec-
tively) or an AVA of 1.5 cm2 or greater (76%  5% and
61%  6%, respectively; P< .001; Figure 1). Survival
with an AVA of 1.0 to 1.5 cm2 and an AVA of 1.5 cm2 or
greater was not different (P ¼ .25). With similar adjust-
ment, an indexed AVA of less than 0.6 cm2/m2 predicted
survival (adjusted RR, 1.63; 95% CI, 1.11–2.36; P ¼ .01)
equal to that of unindexed AVA but did not add predictive
power (P> .10). Symptoms less severe than class III-IV,diovascular Surgery c Volume 144, Number 6 1423
FIGURE 1. Survival during medical management of Olmsted County,
Minnesota, residents after the diagnosis of aortic stenosis (AS) according
to baseline aortic valve area (AVA). The numbers along each curve indicate
the survival at 5 and 8 years. Note the excess mortality associated with an
AVA less than 1.0 cm2.
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not add predictive power (all P>.20).
The observed versus expected survival rates were com-
pared, stratified by functional class and an AVA less than
1.0 cm2 (Figure 2), with the RRs of the observed/expected
mortality listed in Table 2. Class III-IV symptoms were
associated with similar excess mortality with an AVA of
less than 1.0 cm2 or 1.0 cm2 or greater However, the entire
group of patients with an AVA of 1.0 cm2 or greater had
no excess mortality. In contrast, the patients with an AVA
of less than 1.0 cm2 had uniform excess mortality versusFIGURE 2. Survival during medical management in Olmsted County, Minnes
pected survival specific to each subset, according to aortic valve area (AVA) (<1.
class I (no angina or dyspnea); Middle, patients in class II (minimal angina or d
served survival (thick line) and expected survival (thin line) shown with 5-year r
to their comparison. Note, that class III-IV symptoms were associated with exce
1.0 cm2 incurred excess mortality compared with that expected in those with s
1424 The Journal of Thoracic and Cardiovascular Surexpected with RRs close to 2.0, irrespective of symptoms,
even with an EF of 50% or greater or MnG less than 40
mm Hg (P ¼ .02). Class III-IV symptoms identified 11%
of patients as at a high risk of death versus 27% by an
AVA less than 1.0 cm2. The c-statistics showed that an
AVA less than 1.0 cm2 predicted survival better than class
III-IV symptoms (P¼ .05). However, class III-IV symptoms
showed greater specificity (P<.0001) and an AVA less than
1.0 cm2 greater sensitivity (P¼ .003) in predictingmortality.CHF With Medical Management
With conservative management, 80 patients developed
CHF (10-year incidence, 39%  4%). On multivariate
analysis, adjusting for age, atrial fibrillation, and comorbid-
ity, the EF (adjusted RR, 0.97; 95% CI, 0.96–0.99, per
1-point increase; P< .01) and an AVA less than 1.0 cm2
(adjusted RR, 2.3; 95% CI, 1.3–4.0; P<.01; Figure 3) in-
dependently predictedCHFduring follow-up,with a border-
line effect of class III-IV symptoms (adjusted RR, 1.82;
95% CI, 0.95–3.3; P ¼ .07). No other symptomatic cate-
gory or objective measure of AS severity predicted CHF
(all P>.10). The indexed AVA predicted CHF but did not
add to the models with unindexed AVA (P ¼ .77). For pre-
dicting CHF, an AVA less than 1.0 cm2 was superior to the
MnG, peak velocity, and stroke work loss (all P<.06) but
similar to an indexed AVA less than 0.6 cm2/m2 (P ¼ .67).AVR and Outcome
AVR was performed in 131 patients (at age 72  12
years) and 69 (53%) underwent concomitant coronaryota, residents after diagnosis of aortic stenosis (AS) compared with the ex-
0 or1.0 cm2) and functional class at diagnosis. Left, patients in functional
yspnea); and Right, patients in class III-IV (severe angina or dyspnea). Ob-
ates indicated (bold, observed; thin italicized, expected), and P values refer
ss mortality, irrespective of AS severity. Also, patients with AVA less than
evere, minimal, or even absent symptoms of angina and dyspnea.
gery c December 2012
TABLE 2. Relative risk of excess mortality (compared with expected
mortality in Minnesota whites) after diagnosis of aortic stenosis
according to aortic valve area and symptoms at diagnosis
AVA (cm2) Overall cohort
Functional symptom class*
I II III-IV
1.0
Risk ratio 1.11 1.14 0.87 1.81
95% CI 0.92–1.33 0.88–1.45 0.60–1.22 1.10–2.80
P value .25 .30 .42 <.01
<1.0
Risk ratio 1.78 1.65 1.81 2.17
95% CI 1.33–2.35 1.05–2.47 1.09–2.83 1.03–4.13
P value <.001 .02 <.01 .02
Data are presented as the risk ratio of observed to expected survival, with 95% CIs
and corresponding P value. AVA, Aortic valve area; CI, confidence interval. *Class
I, those with no angina and no dyspnea; class II, those with minimal angina or dysp-
nea; and class III-IV, those with severe dyspnea or angina at diagnosis.
Malouf et al Acquired Cardiovascular Disease
A
C
Dbypass grafting. Most patients had cardiac symptoms before
surgery (92%) but so did 67% of unoperated patients. After
valve replacement, 50 patients died, including 4 (3%) peri-
operatively. AVR was ultimately performed in 43 (45%) of
96, 58 (33%) of 175, and 30 (34%) of 89 patients with an
AVA less than 1.0, 1 to 1.5, and 1.5 cm2 or greater at diag-
nosis, representing a 5-year incidence (accounting for those
remaining at risk) of 55%  7%, 17%  3%, and 9% 
3% (P<.001). Adjusting for age, sex, comorbidity, atrial
fibrillation, EF, and class III-IV symptoms, AVR was per-
formed more frequently with an AVA less than 1.0 cm2
(adjusted RR, 2.8; 95% CI, 1.6–4.6; P< .001) and MnG
of 40 mm Hg or greater (adjusted RR, 5.8; 95% CI, 3.0–
11.1; P<.001). Unoperated versus operated patients with
an AVA less than 1.0 cm2 had a lower MnG (29  15 vs
45  20 mm Hg, P<.001), were older (84  11 vs 68 
15 years, P<.001), and were more often women (72% vsFIGURE 3. Incidence of congestive heart failure (CHF) during medical
management in Olmsted County, Minnesota, residents after the diagnosis
of aortic stenosis (AS) according to the baseline aortic valve area (AVA).
The numbers along each curve indicate the rates of heart failure at 5 and
8 years. Note the excess heart failure incidence associated with an AVA
less than 1.0 cm2.
The Journal of Thoracic and Car35%, P<.001). Multiple reasons were cited as justification
for not performing AVR, including AS judged not severe
(57%) mostly based on low gradient, patient’s age too great
(24%), comorbidities (37%), symptoms judged equivocal
(43%), patients with no interest in surgery (20%), and phy-
sician choice (20%). Patients with an AVA less than 1.0 cm2
with discordant versus concordant velocity/gradient under-
went less valve replacement (5-year incidence, 44% 9 vs
69%  9%; P< .001) and had lower overall (including
postoperative) survival (5-year survival, 47%  7 vs
69%  8%; P ¼ .01), even after adjustment (adjusted
RR, 1.67; 95% CI, 1.01–2.81; P ¼ .04) for age, sex, and
EF. Adjusting for age, sex, EF, Charlson co-morbidity in-
dex, and AVA, AVR was associated with subsequent de-
creased mortality (adjusted RR, 0.61; 95% CI, 0.39–0.94;
P ¼ .02) and CHF (adjusted RR, 0.29; 95% CI, 0.13–
0.64; P<.01), irrespective of the gradient (P>.40).
DISCUSSION
This first comprehensive study of patients with AS diag-
nosed in a community medical practice revealed new infor-
mation on the current presentation and outcomes of patients
with AS. In the current era, AS is first diagnosed in an el-
derly population whose presentation is challenging. Despite
the exclusion of severe comorbidities, symptoms were fre-
quent, were not linked to AS severity, and were insensitive
outcome predictors. Also, severe AS most often presented
with a low gradient despite a normal EF, leading to potential
underestimation of its severity. The preeminent and most
sensitive objective marker of outcome was an AVA of less
than 1.0 cm2, even in patients with low-gradient AS despite
a normal EF. An AVA of less than 1.0 cm2 was associated
with excess mortality and CHF, even in asymptomatic pa-
tients. AVR markedly reduced the risk of death or CHF
but was performed in few patients with severe stenosis, par-
ticularly those with low-gradient AS. Although in elderly
patients, individualized clinical decisions are warranted,
awareness that an AVA of less than 1.0 cm2 implies a high
risk, irrespective of symptoms or gradient, should lead pa-
tients with confirmed severe AS to carefully and individu-
ally consider AVR.
Challenging Presentation of AS in the Community
Although AS is a classic valve disease, epidemiologic
changes2 have profoundly affected this supposedly well-
known condition. Currently, AS is usually degenerative
and affects the elderly,2 deeply contrasting with the mid-
20th century predominance of rheumatic stenosis affecting
patients typically 50 to 60 years old.15 Our results have
shown that the constructs developed in the 1960s8 of pa-
tients with high-gradient AS remaining asymptomatic for
a long period and then developing clearly defined symptoms
heralding poor outcomes, are not congruent with current re-
alities. The current challenging AS presentation could notdiovascular Surgery c Volume 144, Number 6 1425
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segmented a priori AS subsets rather than
comprehensively enrolling all patients. With advancing
age at diagnosis, comorbidities and inactivity hinder
symptom assessment. With all cases of diagnosed AS
gathered, we noted that symptoms labeled as cardiac
symptoms are frequent and not specific to AS severity.
Thus, the mediocre quality of the link between symptoms
and outcome is logical. Furthermore, the disconnection
between symptoms and surgical referral does not reveal
poor clinical practice but rather the difficult interpretation
of a challenging presentation. Another presentation
challenge is the frequency of severe AS with a low
gradient. A low gradient resulting from a low EF and its
poor prognosis is well known16; however, severe AS with
a low gradient owing to a lower stroke volume despite a nor-
mal EF is less recognized. This entity was recently empha-
sized11 but has been disputed out of concern for calculation
inaccuracy,17 because an underestimation of the aortic an-
nular diameter could lead to a spuriously low AVA. How-
ever, these technical concerns are superseded by the
observed outcomes in the community, demonstrating, de-
spite a benign appearance, that this particular form of AS
has a poor prognosis11 that is alleviated by AVR.11 Never-
theless, this challenging presentation leads to hesitations
in indicating surgical treatment that has major implications
for the outcomes.
Outcome of AS in the Community
Series from referral centers affected by selection
biases6,9,10 showed wide discrepancies in 5-year survival
of 38% to 83% and outcomes qualified as benign to
malignant.6,9,10 Discrepancies can also stem from short
follow-up9 and the selection of young patients.9 Our com-
prehensive community study has shown that AS is a serious
disease, with excess mortality increasing progressively after
diagnosis with an AVA of less than 1.0 cm2, generally leav-
ing time to give careful consideration to therapeutic options.
Our community study of all patients with AS has shown that
the theoretical constructs of low- and high-risk subsets ac-
cording to the symptoms or gradient, although conceptually
attractive,3 were not successful in reality as predictors of
outcome. ‘‘Asymptomatic’’ patients, long considered at
low risk,8 incur notable risks of sudden death6 and long-
term mortality,6,10 possibly because of underestimated
functional impairment.18 Symptoms, when present, were
not helpful in determining the prognosis and were not spe-
cific of severe AS. In our series, only class III-IV symptoms
predicted mortality but were insensitive and not AS spe-
cific. Our data do not obviate the need for surgery in severe
AS with class III-IV symptoms3 but emphasize the limita-
tions of a watchful symptom-based approach.9
In this era of poor symptom reliability, resulting from
age, inactivity, or comorbidity, it is essential to define1426 The Journal of Thoracic and Cardiovascular Surclearly objective risk markers. A low EF is a well-
established high-risk marker that was confirmed in our
community.16 However, the risks attached to low EF persist
after surgery19 such that intervening at that stage is required
but not desirable. Doppler measures have been disputed.
Some studies used peak velocity,6,9 others the AVA10,18 or
more complex indexes,20 with variable thresholds and
none have compared the value of these markers. Our data
with a minimized referral bias have shown that an AVA of
less than 1.0 cm2 is the preeminent, powerful, and sensitive
marker of mortality and CHF. The greater sensitivity of an
AVA less than 1.0 cm2 is related to the detection of patients
at high risk despite the combination of a low gradient and
normal EF. However, in clinical practice, considering sur-
gery in elderly patients with low-gradient AS requires con-
firmation that the aortic valve disease is severe using either
catheterization or new noninvasive computed tomography
quantitation of aortic valve calcification load.21 This tech-
nique measures the intrinsic valve lesion mechanistic to
AS22 and is simple, accurate, and clinically relevant.21
Thus, in elderly patients, confirming severe AS is possible
according to either high gradient or high calcification load
(in thosewith low-gradient AS), which has important impli-
cations for the indication of AVR.
AVR and Outcomes
Medical therapy is ineffective in preventing stenosis pro-
gression, and AVR is the only approved treatment of AS.3 It
markedly reduces mortality and CHF and has low operative
risk19; however, it is often delayed or not performed in se-
vere AS, even with severe symptoms.4,6,10,16 Emphasis
has been placed on the hazard of overestimating surgical
risk; however, surgical deferral might be appropriate in
some very elderly patients with overwhelming
comorbidity.23 However, most often the nonindication for
AVR results from the challenging presentation, involving
poorly decipherable symptoms and/or low-gradient AS.11
In the future, this unmet need for treatment might be better
addressed by further declining operative risks23 and by new
percutaneous valve replacement.24 With problematic symp-
tom assessment and serious outcome consequences of an
AVA less than 1.0 cm2 even without symptoms, we believe
a more proactive approach to AS should be considered. Ob-
taining confirmation of AS severity with an AVA of less
than 1.0 cm2 and low gradient is essential to timely discuss
surgical treatment individualized to the patient’s age and
comorbidities.
Study Limitations
Our series is not the largest assessing the outcomes of
AS.6,10 Our large referral practice would considerably
increase the sample but with the limitations of referral
bias.25 Data from an entire community medical practice25
have reconciled previous widely variable survival estimatesgery c December 2012
Malouf et al Acquired Cardiovascular Diseasefrom referral centers and the high event numbers provided
ample power. Determining the cause of death in an elderly
population and its link to AS was not consistently feasible.
However, the mortality–severity association and the exclu-
sion of severe comorbid conditions support a link between
severe AS and excess mortality after diagnosis. The retro-
spective identification and chart review is a limitation but
offers the only option to identify all community patients
with AS in a large practice. The recommendation for
AVR was determined by the personal physicians and not
from a predefined strategy.3 Thus, our study could not re-
veal the advantages of 1 treatment strategy over another
but measured the performance and effect of AVR on out-
comes in routine medical practice.A
C
DCONCLUSIONS
In the community, AS generally affects the elderly with
a challenging presentation. Symptoms are frequent but of-
ten discordant with AS severity and are problematic to inter-
pret. Furthermore, severe AS often presents with a low
gradient despite a normal EF. In predicting the outcome,
symptoms (class III-IV) are insensitive risk markers. An
AVA of less than 1.0 cm2 is the most powerful and sensitive
predictor of severe outcomes with a close to doubling of
death and CHF risk and excess mortality compared with
that expected. The excess risk attached to AVA of less
than 1.0 cm2 was present even in those without symptoms
and/or with low-gradient AS. AVR improves outcome but
is performed in few patients, particularly among those
with a low gradient despite severe AS. Thus, the presently
demonstrated challenging presentation and incompletely
met need for treatment of AS suggest that, in patients
with an AVA of less than 1.0 cm2, a thorough evaluation
and prudent AVR considerations are warranted.References
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